Aren't the options double hormone blockade or triplet? Or if BRCA then perhaps PARPi? But you said ADT with optional...

Let me clarify the current guidelines for advanced prostate cancer treatment options:

According to the NCCN Guidelines (2023):

1. Genetic testing is actually recommended for all patients with metastatic prostate cancer to identify actionable mutations (including BRCA1/2)
2. For metastatic hormone-sensitive prostate cancer (mHSPC), the preferred regimens include:

• ADT + Abiraterone
• ADT + Docetaxel
• ADT + Enzalutamide
• ADT + Apalutamide
• ADT + Darolutamide

The ASCO Guidelines (2023) specifically endorse "triplet therapy" combining:

• ADT + Novel Hormonal Agent (like enzalutamide/abiraterone) + Docetaxel for high-volume mHSPC

Regarding PARP inhibitors: The NCCN Guidelines indicate that for patients with mutations in homologous recombination repair genes (like BRCA1/2), PARP inhibitors (olaparib or rucaparib) are appropriate options after progression on initial therapy.

You are correct that I should have mentioned:

1. The importance of genetic testing
2. Triplet therapy as an option for eligible patients
3. The potential role of PARP inhibitors for those with relevant mutations

Always consult with your oncologist about which approach is most appropriate for your specific situation, as factors like disease volume, genetic profile, and overall health influence treatment selection.